Investigators evaluated atezolizumab combined with bevacizumab and non–platinum-based chemotherapy for patients with recurrent ovarian cancer.

Elahere showed superior efficacy over chemotherapy in progression-free survival, objective response rate, and overall survival in the MIRASOL trial. The treatment reduced the risk of tumor progression ...

Keytruda with paclitaxel, with or without Avastin, improved PFS and OS in PRROC patients, irrespective of PD-L1 status. The trial showed significant benefits in both CPS ≥1 and intention-to-treat ...

Four leading ovarian cancer research charities from four countries are funding a new AI Accelerator Grant in partnership with Microsoft's AI for Good Lab to supercharge the next cancer research ...

Ovarian cancer mortality rates have declined, but disparities persist across age, race, and geographic regions. Older women, non-Hispanic White women, and those in the Northeast and Midwest have ...

Wistar Institute scientist Maureen Murphy wants to solve a decades-long mystery: Why is ovarian cancer often resistant to hormone therapy? In a recently published study, she shared a new theory as to ...

BERLIN — The combination of pembrolizumab with weekly paclitaxel, with or without bevacizumab, leads to significant improvements in survival outcomes in patients with platinum-resistant recurrent ...

Ovarian cancer mortality has declined, but racial and age disparities persist, with non-Hispanic White patients having the highest AAMRs. Non-Hispanic Asian or Pacific Islander populations show the ...

The World Ovarian Cancer Coalition announced that a groundbreaking international study, "Experiences of Women with Ovarian Cancer in 22 Low- and Middle- Income Countries (Every Wo ...

Subscribe to The St. Louis American‘s free weekly newsletter for critical stories, community voices, and insights that matter. Sign up Ovarian cancer is the deadliest of all gynecologic cancers, and ...